Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes

Maka S Hedrington, Ana Tsiskarishvili, Stephen N Davis
  • Expert Opinion on Biological Therapy, February 2018, Taylor & Francis
  • DOI: 10.1080/14712598.2018.1439014
The author haven't yet claimed this publicationThe author haven't yet claimed this publication

In partnership with: